Three-Year Outcomes of Intravitreal Aflibercept versus Laser Therapy for Retinopathy of Prematurity: Interim Analysis of the Efficacy and Safety Outcomes in the FIREFLEYE next Trial

Descriptive analyses of the 3-year outcomes confirm long-term, stable disease control following aflibercept 0.4 mg treatment of severe acute-phase ROP, with age-appropriate visual function, less frequent/severe myopia compared with laser, and no ocular or systemic safety concerns.

Authors

Institutions

Publication Details

Journal
Neonatology
Published
2026-01-08
DOI
https://doi.org/10.1159/000549717
Primary Topic
Retinopathy of Prematurity Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Three-Year Outcomes of Intravitreal Aflibercept versus Laser Therapy for Retinopathy of Prematurity: Interim Analysis of the Efficacy and Safety Outcomes in the FIREFLEYE next Trial

Katja Brandau, Alistair R. Fielder, Tobias Niesen, Robert Vitti et al.
Neonatology
Retinopathy of Prematurity Studies
article

Three-Year Outcomes of Intravitreal Aflibercept versus Laser Therapy for Retinopathy of Prematurity: Interim Analysis of the Efficacy and Safety Outcomes in the FIREFLEYE next Trial

Katja Brandau, Alistair R. Fielder, Tobias Niesen, Robert Vitti, Sarah Schlief, Aditya Athanikar, Karen Chu, Wei-Chi Wu, Evra Köfüncü, Thomas Miller, Carlos Jacas, Andreas Stahl, On behalf of the Dutch Hepatocellular & Cholangiocarcinoma Group (DHCG), Domenico Lepore, Hidehiko Nakanishi, Sergio Leal, Pablo Iveli, Fei Zhao
article en

Abstract

Descriptive analyses of the 3-year outcomes confirm long-term, stable disease control following aflibercept 0.4 mg treatment of severe acute-phase ROP, with age-appropriate visual function, less frequent/severe myopia compared with laser, and no ocular or systemic safety concerns.

Neonatology
Università Cattolica del Sacro Cuore (IT), Bayer (United States) (US), St George's, University of London (GB), Chang Gung University (TW), City, University of London (GB), Regeneron (United States) (US), Universitätsmedizin Greifswald (DE), Bayer (Canada) (CA), Linkou Chang Gung Memorial Hospital (TW), Bayer (Switzerland) (CH), Vall d'Hebron Hospital Universitari (ES), Kitasato University (JP), Bayer (Germany) (DE)
Good health and well-being
Openalex Percentile: Top 94%
Retinopathy of Prematurity Studies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Three-Year Outcomes of Intravitreal Aflibercept versus Laser Therapy for Retinopathy of Prematurity: Interim Analysis of the Efficacy and Safety Outcomes in the FIREFLEYE next Trial — Katja Brandau, Alistair R. Fielder, et al. · Neonatology (2026) | TGRS Research Map | TGRS